Latest signal
last curated pass Oct 28, 2026 · 8 public entries · source-aware summaries from 6 legacy curated cards plus llm-wiki tweets
Recent curated signals
Sleep “We hung out in the dark and it was so much better”: the stage-lights anecdote is the feed’s second evidence-aligned sleep post in two days — the direction verifies against the canonical blue-light RCT, but the post itself is an unmeasured N=1 event story Johnson posted an event anecdote: “The lights pointing at the stage were blasting my eyeballs with blue light which makes it harder to fall asleep and fragments sleep. / So we hung out in the dark and it was so much better.” (761 likes, 7 reposts, 73 replies; October 28, 12:47 UTC). The mechanism direction is among the best-replicated findings in sleep research: in the canonical 5-night randomized crossover, reading a light-emitting e-book before bed versus a print book suppressed evening melatonin by 55.12%, delayed dim-light melatonin onset by more than 1.5 hours, lengthened sleep latency by roughly 10 minutes (25.65 vs 15.75 minutes), reduced REM sleep, and left readers sleepier the next morning (Chang, Aeschbach, Duffy, Czeisler, PNAS 2015, 10.1073/pnas.1418490112) — with the device spectrum peaking at 452 nm in the blue range the post names. The boundaries the post drops: the laboratory exposed participants at controlled illuminance for fixed durations, while the post is an unmeasured single-evening story — no lux reading, no exposure duration, no sleep data, and “so much better” is a subjective impression; the post names no study; and evening-light avoidance is general sleep hygiene, which the AASM suggests against as a stand-alone therapy for chronic insomnia disorder (Edinger et al., J Clin Sleep Med 2021, 10.5664/jcsm.8988). The dashboard records an attributed anecdote with a well-verified direction — not a measured result, a reader light-exposure protocol, or medical advice. 3 sourcesEvening blue light / melatonin / sleep onset Research claim “Slowing aging after the age 50 can add 3.6 yrs of life and is worth $4 million”: the relay traces to a real three-week-old modeling paper — the lifespan figure verifies as a round-up, and the money figure is a willingness-to-pay construct the post inflates and converts to cash-sounding dollars Johnson posted: “Slowing aging after the age 50 can add 3.6 yrs of life and is worth $4 million in economic value” (437 likes, 15 reposts, 56 replies; October 28, 14:01 UTC), with an attached chart screenshot OCR-identified as Felizzi, “Economic impact of biomarker-based aging interventions on healthcare costs and individual value,” Frontiers in Genetics, published October 11, 2026 (10.3389/fgene.2026.1814599). The paper is real and the relay is close: a single-author Hypothesis & Theory modeling study by an enGene (Basel) industry author that chains the DunedinPACE epigenetic clock (via Mak et al. 2023 frailty coupling, 10.1093/gerona/glad251) to Swiss-calibrated survival, frailty-prevalence, and healthcare-cost data, simulating three intervention scenarios starting at age 50. The lifespan figure verifies as a round-up: the most optimistic scenario (CR2, interventions assumed to hold the pace of aging at 1.0) yields a 3.58-year life-expectancy gain — the moderate scenario (CR1) gives 2.89. The money figure drifts twice. First, the paper’s most optimistic total individual value is CHF 3,236,195 — roughly $3.5–3.6 million at recent exchange rates, so “$4 million” overstates the paper’s own headline by about a tenth. Second, and larger: that figure is a willingness-to-pay construct — CHF 1,216,186 survival value plus CHF 2,020,009 health-quality value, undiscounted, in the Murphy–Topel/Scott value-of-life framework — a welfare measure of what a person would rationally pay for the assumed health and longevity gains, not cash, income, or savings. The modeled healthcare-system savings are CHF 131,608 per person over 40 years, and the paper itself reports the healthcare case becomes cost-sensitive once CHF 600 twice-yearly DunedinPACE testing is included, while the individual-value case stays positive. Boundaries the post drops: CR2 assumes an intervention can hold biological aging pace at 1.0 — assumed, not demonstrated by any available treatment; DunedinPACE captures one DNA-methylation axis of aging by the paper’s own caveat; costs and life tables are Swiss; the author is a longevity-industry employee framing the work explicitly around consumer business models; and the post names no study. The dashboard records an attributed research relay with a verified paper, a rounded lifespan figure, and a converted, inflated value construct — not evidence that any available intervention adds 3.6 years of life, a wealth or savings figure, or medical advice. 4 sourcesLongevity economics / DunedinPACE / willingness-to-pay modeling N=1 test “I got mine to zero. The first documented case”: the feed’s semen-microplastics relay verifies study-for-study — the UNM testis and 113-man China semen papers are real and quoted closely — while the “first documented case” of zero is an unreplicated, specialty-lab N=1 with no published method Johnson posted the feed’s most detailed microplastics relay yet, quote-posting his own May 7, 2026 “I HAVE NO MICROPLASTICS IN MY BALLS” post: “Up to 100% of men have microplastics in their semen / I got mine to zero. The first documented case. / A 2024 study detected microplastics in 100% of human and dog testicular tissue. / In another study, microplastics were detected in the semen and urine of all of 113 tested men from China. / Researchers broke down plastic type and how they affected sperm quality. / The most common came from packaging (polystyrene, polypropylene, and polyethylene). / PTFE, the synthetic polymer used in non-stick Teflon pans, proved the most lethal, creating 11% lower sperm concentration and 9% fewer total sperm. / Ten studies have measured microplastics in human semen. Five found 100% detection. / The rest from 84% down to 37%, but older tests used standard infrared microscopes that are blind to particles smaller than 10–20 microns. Newer studies used Raman spectroscopy, which can spot particles down to 1 micron. / So in short, 100% prevalence is plausible if not likely.” (1,428 likes, 65 reposts, 104 replies; October 27, 17:37 UTC). Both named studies verify precisely. First: Hu, Garcia, Nihart, Campen et al., “Microplastic presence in dog and human testis…,” Toxicological Sciences, August 2024 (10.1093/toxsci/kfae060) — pyrolysis-GC/MS found microplastics in all 47 canine and all 23 human testes (human mean 328.44 µg/g, PE dominant), exactly “100% of human and dog testicular tissue,” with the authors’ own caveats that postmortem samples “typically did not experience a natural death,” the method is still being refined, and associations “do not imply causality.” Second: “Association of mixed exposure to microplastics with sperm dysfunction: a multi-site study in China,” eBioMedicine, July 2024 (10.1016/j.ebiom.2024.105369) — Raman microscopy on 113 men recruited at three reproductive-medicine centers found microplastics in all semen and urine samples (typically 3–5 polymer types; PS/PP/PE most detected, matching “most common came from packaging”), and PTFE-exposed participants showed lower sperm concentration (52.13 vs 58.32 million/mL, p=0.041 — the post’s “11% lower” is 10.6% rounded) and total sperm count (188.90 vs 207.67 million — the post’s “9% fewer”), with logistic-regression OR 4.32 for reduced concentration; the authors’ stated limits: cross-sectional, association not causation, no exposure concentrations, and a fertility-clinic population. The “ten studies / five at 100%” tally is consistent with the published semen-MP literature (100% cohorts: the 36-man Jinan general-population Raman study, Sci Total Environ 2024; the 113-man eBioMedicine study; a 115-man Malaysian Raman cohort detected MPs in all samples) and with detection-frequency reviews noting older FTIR/LD-IR work at lower rates (Zhao et al. 2023: 11/25; MDPI Toxics 2025: 34/45 = 75.6%; Tagliabue et al. 10.1016/j.scitotenv.2023.165922: 6/10) — though Johnson’s exact “84% down to 37%” endpoints match no single published tally we could identify, and his “Raman spots particles down to 1 micron” compresses that Raman resolves sub-micron in principle while real-world bio-matrix protocols vary. The boundaries the relay drops: his own zero result is a self-reported specialty-lab test with no published method, no third-party replication, and no pre-registration — in his own reply he concedes “This test is not widely available, sadly. I had a specialty lab create the test for me and conduct the analysis. It would be great if someone made a test widely available” (60 likes; 17:56 UTC) — so “first documented case” means first self-reported case; the underlying studies are cross-sectional associations in fertility-clinic or postmortem populations, not dose-response evidence that Teflon pans lower sperm counts in readers; and microplastics methodology reviews (Arch Toxicol 2026, 10.1007/s00204-026-04392-1) flag unstandardized nomenclature, small samples, and contamination risk across the whole field, which cuts at “zero” and “100%” claims alike. The dashboard records an attributed research relay with two verified studies and an unreplicated N=1 centerpiece—not evidence that non-stick pans harm readers’ fertility, a validated zero-microplastics protocol, a reader testing recommendation, or medical advice. 6 sourcesMicroplastics / semen / sperm quality / N=1 testing Measurement “My body is indistinguishable from an elite athlete”: the twice-yearly MRI readout returns with 20s-equivalent fat and heart scores — self-reported scan impressions, a radiologist quote converted into a radiologist “report,” and the ACR still does not recommend whole-body MRI screening for asymptomatic people Johnson posted his twice-yearly MRI results with an attached report image: “my twice yearly mri results / > subcutaneous and visceral fat - 20s equivalent / > heart 100% score - 20s equivalent / > hippocampal occupancy - 99th percentile / radiologist report: / > my body is indistinguishable from an elite athlete / healthy bodies... / > make more money / > have more sex / > are more fun” (303 likes, 7 reposts, 50 replies; October 27, 21:55 UTC), following up a minute later that “mri scan was done with @prenuvo” (14 likes). The scanner and cadence are consistent with his established disclosure pattern: Prenuvo is the direct-to-consumer whole-body MRI company whose scans he has attributed his imaging to since his public protocol records, and “twice yearly” matches the twice-a-year cadence he has referenced since mid-2025. But the numbers are his summary of a private report he has not published: “20s equivalent” fat and heart scores, a “100%” heart score, and “99th percentile” hippocampal occupancy name no reference cohort, no normative dataset, and no scoring method — the same undisclosed-cohort pattern the dashboard has recorded on every percentile stack (“I am 18,” the Kernel brain-scan percentiles, the October 22 “you look your age” comeback). The line “radiologist report: my body is indistinguishable from an elite athlete” upgrades a quoted verbal impression to the status of a document, and the “healthy bodies make more money / have more sex / are more fun” coda is the same status pitch the feed attached to the October 22 percentile post. The context the post omits: no professional body recommends whole-body MRI screening of asymptomatic people — the American College of Radiology “does not believe there is sufficient evidence to justify recommending total body screening for patients with no clinical symptoms, risk factors or a family history” (ACR statement, April 17, 2023), RANZCR does not recommend it (position statement, July 2025), and the largest systematic review (J Magn Reson Imaging 2019, 10.1002/jmri.26736; 12 studies, 5,373 asymptomatic adults) found a pooled 32.1% prevalence of critical-or-indeterminate incidental findings with a substantial false-positive proportion (16.0% pooled) and no long-term verification of negative scans — the incidentaloma-and-overdiagnosis trade a screening-adjacent post never mentions. The boundaries: all figures are self-reported impressions of an unpublished report; “indistinguishable from an elite athlete” is an attributed quote, not a clinical finding; the scan was paid consumer screening, not a diagnostic workup; and nothing here is evidence that twice-yearly whole-body MRI improves health outcomes for anyone. The dashboard records an attributed measurement disclosure with verified screening-policy context—not a reader imaging recommendation, evidence of youthful equivalence, or medical advice. 4 sourcesWhole-body MRI / imaging screening / Prenuvo Sleep “Your bedroom should be cold, dark and boring”: the feed’s highest-engagement post of the window is also its most evidence-aligned — the directive is a near-verbatim compression of stimulus control, the AASM-endorsed insomnia therapy whose core instruction is to keep the bedroom for sleep Johnson posted the window’s highest-engagement message (10,810 likes — the feed’s biggest post since the sleep-deviation meme): “Your bedroom should be cold, dark and boring. / If it’s also your office, gym and movie theater, your brain never gets the signal that it’s time to sleep.” (10,810 likes, 309 reposts, 269 replies; October 27, 13:47 UTC). This is the feed’s first standalone sleep-environment directive, and it aligns with the clinical literature more closely than most of what the feed publishes: the middle sentence is a plain-language compression of stimulus control therapy, one of the two core behavioral components of CBT-I, whose defining instruction set — “use the bed/bedroom for sleep and sex only (no reading, watching TV, etc. in bed)” — exists precisely to “extinguish the association between the bed/bedroom and wakefulness” (AASM clinical practice guideline, Edinger et al., J Clin Sleep Med 2021, 10.5664/jcsm.8988: stimulus control is a suggested single-component therapy for chronic insomnia disorder, and multicomponent CBT-I is the strong first-line recommendation). The cold/dark legs trace to the same consensus literature his own sleep-duration guidance already cites: the NSF 2017 consensus identifies a “cold bedroom” among environmental sleep factors, and cool ambient temperature is the standard thermoregulatory guidance for sleep onset, while “dark” maps to light-suppression advice. The boundaries: the post names no study, as always; it is general sleep hygiene rather than an insomnia treatment — and the AASM specifically suggests against sleep hygiene as a stand-alone therapy for chronic insomnia disorder, because environmental advice alone does not treat established insomnia; the “your brain never gets the signal” mechanism is a fair lay rendering of conditioned-arousal theory but is his gloss, not a cited finding; and general-population sleep advice is not a substitute for CBT-I or clinical care for someone with an insomnia disorder. The dashboard records an attributed sleep-environment directive that compresses real, guideline-endorsed behavioral therapy—not a reader insomnia treatment, a clinical protocol, or medical advice. 3 sourcesSleep environment / stimulus control / sleep hygiene Research claim “Extends the medium lifespan of male mice by 22.5% and 35% in female mice”: the IL-11 relay is a real, landmark Nature paper — but the female figure is wrong in the paper, wrong against Johnson’s own 2024 post, and the relay inherits a quote-post’s framing Johnson quote-posted Ryan Bethencourt’s same-age-mice photo (“the human equivalent of 85… the mouse on the right was given an antibody blocking a single inflammatory protein (IL-11) starting in late middle age”) with: “Extends the medium lifespan of male mice by 22.5% and 35% in female mice. It’s a few years old, I posted about it in 2024. Showed IL-11 as a driver of aging, and tissue inflammation and fibrosis. It climbed up with age, and was linked to fat build up and muscle loss. It is now in Phase II human clinical trials for lung fibrosis.” (1,048 likes, 51 reposts, 43 replies at curation; October 26, 21:41 UTC). The underlying work verifies in full: Widjaja et al., “Inhibition of IL-11 signalling extends mammalian healthspan and lifespan,” Nature, July 17, 2024 (10.1038/s41586-024-07701-9) — Il11 deletion extended lifespan in both sexes (24.9% averaged across genetic-deletion studies), and anti-IL-11 antibody (X203) from 75 weeks until death extended median lifespan 22.5% in males (130.3→159.6 weeks) and 25% in females (117.1→146.4 weeks), with fewer tumours at autopsy, improved metabolism and muscle function, and the ERK–AMPK–mTORC1 framing the post summarizes; the “Phase II human clinical trials for lung fibrosis” leg also verifies — Boehringer Ingelheim announced a Phase IIa trial of first-in-class IL-11 inhibitor BI 765423 in idiopathic pulmonary fibrosis on January 13, 2026, an asset in-licensed from the same Singapore/Duke-NUS lineage as the mouse work (Lassen Therapeutics’ LASN01 anti-IL-11-receptor antibody completed Phase 1/2a in pulmonary fibrosis and thyroid eye disease). But the relay misquotes its own source: the paper’s female figure is 25%, not 35%, and Johnson’s own July 17, 2024 post (“Treatment with anti-IL-11 from 75 weeks of age until death extends the median lifespan of male mice by 22.5% and of female mice by 25%,” with the same 105-week-old mouse photo) quotes it correctly — so the October 26 version degrades against both the paper and his own earlier post, the same class of transcription drift this dashboard recorded on the bone-pressure figure two days earlier. “Medium lifespan” for “median,” and the quote-post’s 85-human-year framing, are Bethencourt’s glosses; the post names no study. Boundaries: mouse antibody dosing and knockout genetics, no human longevity data; the IPF trial tests lung function, not aging endpoints; the photo pair is one representative image, not the survival curves. The dashboard records an attributed research relay with a verified paper and a drifted figure—not evidence for anti-IL-11 in humans, a drug expectancy, or medical advice. 6 sourcesIL-11 inhibition / anti-aging / mouse lifespan relay Research claim “Another win for psilocybin”: the feed relays a real three-day-old JAMA Psychiatry letter — while calling a 9-person uncontrolled subsample “9 Parkinson’s patients” and dropping every design limitation the authors state Johnson posted the feed’s first psychedelic-research relay: “Another win for psilocybin. In 9 Parkinson’s patients… GDF15 fell > 17.4% after 10 mg > 13.9% after 25 mg. High GDF15 signals mitochondrial failure and neurodegeneration. Inflammation also declined: > IL-6: −17% > IL-8: −20% > hsCRP: −9.6% > IL-10: +2.7% (anti-inflammatory)” (1,741 likes, 180 reposts, 79 replies; October 25, 14:18 UTC, with an attached figure). The study is real and the match is precise: Bradley, Kelley, et al., “Psilocybin and Inflammatory and Mitochondrial Stress Markers in Parkinson Disease,” JAMA Psychiatry research letter, published October 21, 2026 (10.1001/jamapsychiatry.2026.2733) — a secondary analysis of banked blood from the UCSF open-label pilot (NCT04932434; 12 participants with mild-to-moderate Parkinson’s plus depression/anxiety, 10 mg then 25 mg psilocybin with psychotherapy; Bradley et al., Neuropsychopharmacology 2025, 10.1038/s41386-025-02097-0), in which 9 of 12 gave samples, five inflammatory markers fell and were still significantly below baseline a month after the final dose, and the mitochondrial-stress marker GDF15 improved sharply right after dosing then lost the gain by longer-term follow-up. “High GDF15 signals mitochondrial failure and neurodegeneration” is a fair compression of why the marker was chosen (GDF-15 is elevated in mitochondrial disorders and in Parkinson’s serum). But the relay drops every limitation the letter and its authors state: single-arm, no control group, all participants knew they were receiving the drug, inflammatory markers move with sleep, stress, infection, and the depression that was lifting during hours of therapeutic attention; n=9 banked samples from a 12-person safety pilot; GDF15’s gain did not persist at follow-up while inflammation’s did; and co-author disclosures include psychedelic-industry ties. The “another win” framing converts an early biological signal the authors say needs controlled confirmation into a scoreboard result. Boundaries: psilocybin remains a Schedule I investigational substance; no dose, safety, or efficacy information for any reader; a randomized controlled trial (100 participants, UCSF + Yale, Michael J. Fox Foundation funding) is registered but not read out. The dashboard records an attributed research relay with a verified letter and dropped design context—not evidence psilocybin treats Parkinson’s, a psychedelic-use endorsement, or medical advice. 5 sourcesPsilocybin / Parkinson’s / GDF15 / inflammation markers Prevention “How to reduce microplastics”: the feed’s first standalone reader-directed microplastics checklist — each item traces to real food-contact microplastics literature, and the biggest caveats are dose and health outcome, not direction Johnson posted the feed’s first standalone microplastics-reduction directive aimed at readers’ environments: “how to reduce microplastics > glass or steel water bottle > never microwave food in plastic > wood cutting board > reverse osmosis water filter > loose leaf tea with stainless mesh” (4,855 likes, 190 reposts, 215 replies; October 25, 23:18 UTC). Each item traces to published measurement work: microwaving plastic containers releases by far the most microplastics and nanoplastics of any use scenario — up to 4.22 million microplastic and 2.11 billion nanoplastic particles per cm² in 3 minutes for some containers (Hussain et al., ES&T 2023, 10.1021/acs.est.3c04542s release; Environment & Health/ES&T 57:9782); plastic cutting boards shed an estimated 7.4–50.7 g/person-year of microplastics (polyethylene) — tens of millions of particles annually (Chen et al., ES&T 2023, 10.1021/acs.est.3c00924); plastic teabags steep at brewing temperature release on the order of 11.6 billion microplastics and 3.1 billion nanoplastics per cup in the canonical McGill measurement (Hernandez et al., ES&T 2019, 10.1021/acs.est.9b02540), and new head-to-head work finds bagged tea at 555–2,498 particles/cup vs 0.3–2.4 for bulk/loose leaf (Pehlivan & Gedik, npj Science of Food, October 13, 2026, 10.1038/s41538-026-01175-x) — the exact contrast behind “loose leaf tea with stainless mesh.” Glass/steel bottles and reverse-osmosis filtration are consistent with the same food-contact exposure framework; RO is also the filtration route Johnson’s own July sauna checklist and May microplastics-testing narrative already used. Boundaries: exposure-reduction logic is directional, but no study yet demonstrates that reducing these exposures improves human health outcomes — the health-effects literature is still predominantly association- and mechanism-level (cell/animal), and the ES&T cell studies are high-concentration in-vitro work; the checklist names no study; per-item effect sizes and rankings (which of the five moves exposure most) are not established; “never microwave food in plastic” is the strongest-supported single item. The dashboard records an attributed prevention checklist with verified measurement context—not a reader purchasing list, proven health-benefit evidence, or medical advice. 5 sourcesMicroplastics exposure reduction / food-contact plastics
// Reference paths
Move from feed to dossiers
Each route keeps source trails and medical caution visible. Protocol Health
Habits, Longterm, and Don’ts for measurement loops, sleep consistency, oral care, exercise, and experimental-intervention caution.
Protocol LongevityHabits, Longterm, and Don’ts for biomarkers, healthspan basics, critiques, and low-confidence immortality claims.
Protocol NutritionHabits, Longterm, and Don’ts for plant-led meals, Blueprint products, microplastics claims, and metabolic-drug caveats.
Protocol SleepHabits, Longterm, and Don’ts for bedtime discipline, front-loading examples, and metric caution from tweet-backed sources.
Reference Concepts39 source-aware glossary entries, including concepts without dedicated wiki pages yet.
entity BlueprintBlueprint is bryan-johnson's longevity protocol, product company, and public measurement system. It began as Project Blueprint, an N=1 effort to measure Johnson's organs and biological aging, and later became a consumer
concept Blueprint ProtocolThe Blueprint Protocol is bryan-johnson's closed-loop health system: measure body state, consult scientific evidence, implement interventions, measure again, and update. Johnson treats the body as a system whose organs a
concept Don't DieDon't Die is bryan-johnson's community slogan, longevity philosophy, and civilizational frame. The official Don't Die page describes a community “united in defeating all causes of human and planetary death and building a
concept Biomarker-driven longevity protocolsA biomarker-driven longevity protocol is a health system that treats the body as a measurable control system: collect biomarkers, choose interventions, re-measure, and iterate. project-blueprint is the most visible curre
Signal MetricsInspect source velocity by range, content type, and fallback API state.